与帕金森氏症和阿尔茨海默氏症相关的神经保护草药
Georgiana Smaranda Marțiș1, Rodica Ana Ungur2, Anamaria Pop1
1Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, 64 Calea Floresti, 400509 Cluj-Napoca, Romania.
Nutrients
|February 13, 2026
概括
像植物化学物质这样的天然抗氧化剂对治疗神经退行性疾病如帕金森病 (PD) 和阿尔茨海默病 (AD) 有希望. 本综述探讨了用于潜在的PD和AD治疗的草药衍生化合物.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 植物化学 植物化学
背景情况:
- 帕金森病 (PD) 和阿尔茨海默病 (AD) 缺乏确定的治疗方法.
- 粉样蛋白斑块级联抑制剂是主要的预防策略.
- 自然抗氧化剂,特别是植物化学物质,可能有助于神经退行性疾病的管理.
研究的目的:
- 审查有关PD和AD病理生理学的当前研究.
- 分析基于植物化学的PD和AD的治疗,预防和管理策略.
- 为了识别具有治疗PD和AD的潜力的草药衍生化合物.
主要方法:
- 关于PD和AD候选草药的体内/体外研究的文献综述.
- 植物化学性质的分析,重点是化合物 (酸,多,黄).
- 鉴定特定的草本衍生成分,研究其神经保护作用.
主要成果:
- 化合物具有显著的抗氧化特性,对人类健康有益.
- 在PD和AD的临床前研究中,各种草药候选药物及其成分显示出对PD和AD的潜力.
- 特定的植物化学物质已被确定为它们在神经退行模式中的治疗作用.
结论:
- 植物化学物质,特别是,为开发PD和AD的新疗法提供了有希望的途径.
- 对草药化合物的进一步研究可以指导下一代神经保护药物的开发.
- 自然化合物为预防和管理帕金森氏症和阿尔茨海默氏症疾病提供了可行的策略.
相关概念视频
Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...


